In recent years, a new PET compound (anti-3-F-FACBC or F-fluciclovine) was tested for the detection of prostate cancer relapse. Despite very promising results, only preliminary data were available with regard to the comparison to C-choline. The aim of this study was to compare the detection rate of F-FACBC and C-choline in patients presenting a biochemical relapse. PATIENTS AND METHODS: Fifty patients radically treated for prostate cancer and presenting with rising prostate-specific antigen (PSA) levels were consecutively and prospectively enrolled. All the patients were out of hormonal therapy and underwent both C-choline PET/CT and F-fluciclovine PET/CT within 1 week. The results were compared in terms of detection rate on a patient and lesion basis. Furthermore, a more detailed analysis regarding local, lymph node, and bone relapse was performed. RESULTS: On a patient-based analysis, F-fluciclovine detection turned out to be significantly superior to C-choline (P < 0.000001). This result was also true on lesion, lymph node, bone lesion, and local relapse analysis (P < 0.0001 in all the cases). There was no significant difference in terms of target to background of positive lesions between C-choline and F-fluciclovine. When the patients were divided into groups with different PSA levels, F-fluciclovine had a superior detection rate for low, intermediate, and high PSA levels. CONCLUSIONS: In our experimental conditions, F-fluciclovine provided a statistically significant better performance in terms of lesion detection rate as compared with C-choline. However, more studies are required to evaluate the clinical significance of these results in terms of sensitivity, specificity, and accuracy.

Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, et al. (2015). 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse A Comparison to 11C-Choline PET/CT. CLINICAL NUCLEAR MEDICINE, 40(8), E386-E391 [10.1097/RLU.0000000000000849].

18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse A Comparison to 11C-Choline PET/CT

NANNI, CRISTINA;SCHIAVINA, RICCARDO;BRUNOCILLA, EUGENIO;BOSCHI, SIGISMONDO;BORGHESI, MARCO;MARTORANA, GIUSEPPE;FANTI, STEFANO
2015

Abstract

In recent years, a new PET compound (anti-3-F-FACBC or F-fluciclovine) was tested for the detection of prostate cancer relapse. Despite very promising results, only preliminary data were available with regard to the comparison to C-choline. The aim of this study was to compare the detection rate of F-FACBC and C-choline in patients presenting a biochemical relapse. PATIENTS AND METHODS: Fifty patients radically treated for prostate cancer and presenting with rising prostate-specific antigen (PSA) levels were consecutively and prospectively enrolled. All the patients were out of hormonal therapy and underwent both C-choline PET/CT and F-fluciclovine PET/CT within 1 week. The results were compared in terms of detection rate on a patient and lesion basis. Furthermore, a more detailed analysis regarding local, lymph node, and bone relapse was performed. RESULTS: On a patient-based analysis, F-fluciclovine detection turned out to be significantly superior to C-choline (P < 0.000001). This result was also true on lesion, lymph node, bone lesion, and local relapse analysis (P < 0.0001 in all the cases). There was no significant difference in terms of target to background of positive lesions between C-choline and F-fluciclovine. When the patients were divided into groups with different PSA levels, F-fluciclovine had a superior detection rate for low, intermediate, and high PSA levels. CONCLUSIONS: In our experimental conditions, F-fluciclovine provided a statistically significant better performance in terms of lesion detection rate as compared with C-choline. However, more studies are required to evaluate the clinical significance of these results in terms of sensitivity, specificity, and accuracy.
2015
Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, et al. (2015). 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse A Comparison to 11C-Choline PET/CT. CLINICAL NUCLEAR MEDICINE, 40(8), E386-E391 [10.1097/RLU.0000000000000849].
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/506767
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 109
  • ???jsp.display-item.citation.isi??? 98
social impact